Shares of Sanofi SA (ADR) (NYSE:SNY) ended Monday session in green amid volatile trading. The shares closed up +0.63 points or 1.61% at $39.82 with 6.99 million shares getting traded. Post opening the session at $38.88, the shares hit an intraday low of $38.85 and an intraday high of $39.86 and the price vacillated in this range throughout the day. The company has a market cap of $101.40 billion and the numbers of outstanding shares have been calculated to be 1.29 billion shares.
on Sept. 12, 2016 Sanofi and Verily Life Sciences LLC, (formerly Google Life Sciences), an Alphabet company, announced the launch of Onduo, a joint venture created through Sanofi and Verily’s diabetes-focused collaboration. The joint venture is based in Kendall Square in Cambridge. Onduo’s mission is to help people with diabetes live full, healthy lives by developing comprehensive solutions that combine devices, software, medicine, and professional care to enable simple and intelligent disease management.
Under the leadership of Onduo’s newly appointed Chief Executive Officer, Joshua Riff, M.D., M.B.A., the company will leverage Verily’s experience in miniaturized electronics, analytics, and consumer software development, and Sanofi’s clinical expertise and experience in bringing innovative treatments to people living with diabetes. Dr. Riff joins Onduo from Optum, the health services company of UnitedHealth Group, where he was senior vice president of prevention and wellbeing.
“My experience as a physician and in leading consumer health initiatives has shown me the daily burden of living with diabetes,” said Dr. Riff, CEO, Onduo. “From monitoring food intake to testing glucose levels to actively seeking medical care, the challenges both on the physical and mental well-being of a person living with diabetes are incredibly difficult. We want to develop solutions that allow people living with diabetes to focus on the things they love and enjoy in life by providing tools to make dealing with their diabetes less burdensome.”
Initially, Onduo will focus on the type 2 diabetes community, specifically on developing solutions that could help people make better decisions about their day to day health, ranging from improved medication management to improved habits and goals. Over time, the company plans to expand its focus to include the type 1 diabetes community, and eventually to people at risk of developing diabetes with the goal of helping them better prevent the onset of the disease.
Shares of AstraZeneca plc (ADR) (NYSE:AZN) ended Monday session in green amid volatile trading. The shares closed up +1.04 points or 3.23% at $33.24 with 3.60 million shares getting traded. Post opening the session at $32.53, the shares hit an intraday low of $32.47 and an intraday high of $33.34 and the price vacillated in this range throughout the day. The company has a market cap of $81.53 billion and the numbers of outstanding shares have been calculated to be 1.26 billion shares.
AstraZeneca plc (ADR) (AZN) on September 1, 2016 announced results from the SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol LABA (long-acting beta2-adrenergic agonist) safety study showing patients with controlled and uncontrolled asthma had a comparable risk of serious asthma-related events and a lower risk of asthma exacerbations when formoterol was combined with budesonide versus budesonide alone.
The study compared the safety of formoterol, a LABA, used in combination with budesonide, an inhaled corticosteroid (ICS)–the two active therapies in SYMBICORT pressurized metered dose inhaler (pMDI)–against budesonide (pMDI) to evaluate the risk of serious asthma-related events. These events are defined as a composite endpoint of asthma related events including asthma-related deaths, intubations, and hospitalizations, with time to first serious asthma-related event as the primary endpoint.
The results showed a comparable risk of serious asthma-related events when formoterol was combined with budesonide versus budesonide alone. Based on a predefined non-inferiority margin, the upper limit of the 95% confidence interval (CI) for the hazard ratio (HR) of the primary safety endpoint needed to be less than two. As a result, the findings demonstrated statistical non-inferiority of SYMBICORT to budesonide for time to first serious asthma-related event (HR [1.073], 95% CI, [0.698-1.650]). Furthermore, SYMBICORT therapy resulted in a 16.5% lower risk of asthma exacerbations than budesonide (HR, 0.835; 95% CI, 0.745 to 0.937; P = 0.002).